Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30027-0 ◽

2019 ◽

Vol 20 (6) ◽

pp. 849-861 ◽

Cited By ~ 74

Author(s):

Cathy Eng ◽

Tae Won Kim ◽

Johanna Bendell ◽

Guillem Argilés ◽

Niall C Tebbutt ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated ◽

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

The Lancet ◽

10.1016/s0140-6736(14)62004-3 ◽

2015 ◽

Vol 385 (9980) ◽

pp. 1843-1852 ◽

Cited By ~ 254

Author(s):

Lieke H J Simkens ◽

Harm van Tinteren ◽

Anne May ◽

Albert J ten Tije ◽

Geert-Jan M Creemers ◽

...

Keyword(s):

Colorectal Cancer ◽

Maintenance Treatment ◽

Controlled Trial ◽

Phase 3 ◽

Cancer Group ◽

Safety and effectiveness of intravenous iron sucrose versus standard oral iron therapy in pregnant women with moderate-to-severe anaemia in India: a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Global Health ◽

10.1016/s2214-109x(19)30427-9 ◽

2019 ◽

Vol 7 (12) ◽

pp. e1706-e1716 ◽

Cited By ~ 6

Author(s):

Sutapa B Neogi ◽

Niveditha Devasenapathy ◽

Ranjana Singh ◽

Himanshu Bhushan ◽

Duru Shah ◽

...

Keyword(s):

Pregnant Women ◽

Controlled Trial ◽

Intravenous Iron ◽

Severe Anaemia ◽

Iron Sucrose ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Faculty Opinions recommendation of Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717950273.793455532 ◽

2012 ◽

Author(s):

Alexander Eggermont

Keyword(s):

Metastatic Melanoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(18)30269-3 ◽

2018 ◽

Vol 3 (12) ◽

pp. 845-855 ◽

Cited By ~ 5

Author(s):

Alvaro Romera ◽

Sergiy Peredpaya ◽

Yaroslav Shparyk ◽

Igor Bondarenko ◽

Giovanni Mendonça Bariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Controlled Trial ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Randomised Controlled ◽

First Line Treatment

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30452-6 ◽

2020 ◽

Vol 21 (10) ◽

pp. 1317-1330 ◽

Cited By ~ 3

Author(s):

Shaji K Kumar ◽

Susanna J Jacobus ◽

Adam D Cohen ◽

Matthias Weiss ◽

Natalie Callander ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Stem Cell Transplantation ◽

Controlled Trial ◽

Newly Diagnosed ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70549-7 ◽

2014 ◽

Vol 15 (1) ◽

pp. 78-86 ◽

Cited By ~ 290

Author(s):

Hugo E R Ford ◽

Andrea Marshall ◽

John A Bridgewater ◽

Tobias Janowitz ◽

Fareeda Y Coxon ◽

...

Keyword(s):

Controlled Trial ◽

Symptom Control ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(12)60868-x ◽

2012 ◽

Vol 380 (9839) ◽

pp. 358-365 ◽

Cited By ~ 1908

Author(s):

Axel Hauschild ◽

Jean-Jacques Grob ◽

Lev V Demidov ◽

Thomas Jouary ◽

Ralf Gutzmer ◽

...

Keyword(s):

Metastatic Melanoma ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽